Effect of prenatal peroxisome proliferator-activated receptor α (PPARα) agonism on postnatal development

Toxicology

Volumn 276, Issue 1, 2010, Pages 79-84

  Palkar, Prajakta S ^a   Anderson, Cherie R ^a   Ferry, Christina H ^a   Gonzalez, Frank J ^b   Peters, Jeffrey M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Nuclear receptor; Peroxisome proliferator activated receptor ; Postnatal development; Prenatal exposure

Indexed keywords

CLOFIBRATE; PERFLUOROOCTANOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; FETUS; FETUS WEIGHT; GENE EXPRESSION; GENOTYPE; GESTATION PERIOD; IMPLANTATION; LETHALITY; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PERINATAL PERIOD; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT GAIN;

MUS;

EID: 77955658400     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.07.008     Document Type: Article

References (40)

1. Abbott B.D., Wolf C.J., Schmid J.E., Das K.P., Zehr R.D., Helfant L., Nakayama S., Lindstrom A.B., Strynar M.J., Lau C. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-α. Toxicol. Sci. 2007, 98:571-581.
2. Akiyama T.E., Nicol C.J., Fievet C., Staels B., Ward J.M., Auwerx J., Lee S.S., Gonzalez F.J., Peters J.M. Peroxisome proliferator-activated receptor-α regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J. Biol. Chem. 2001, 276:39088-39093.
3. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., Staels B., Auwerx J., Laville M., Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 48:1319-1327.
4. Bility M., Thompson J.T., McKee R.H., David R.M., Butala J.H., Vanden Heuvel J.P., Peters J.M. Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol. Sci. 2004, 82:170-182.
5. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α-β, and -γ in the adult rat. Endocrinology 1996, 137:354-366.
6. Braissant O., Wahli W. Differential expression of peroxisome proliferator-activated receptor-α-β, and -γ during rat embryonic development. Endocrinology 1998, 139:2748-2754.
7. Chang S.C., Das K., Ehresman D.J., Ellefson M.E., Gorman G.S., Hart J.A., Noker P.E., Tan Y.M., Lieder P.H., Lau C., Olsen G.W., Butenhoff J.L. Comparative pharmacokinetics of perfluorobutyrate in rats, mice, monkeys, and humans and relevance to human exposure via drinking water. Toxicol. Sci. 2008, 104:40-53.
8. Cibelli A., Stefanini S., Ceru M.P. Peroxisomal beta-oxidation and catalase activities in fetal rat liver: effect of maternal treatment with clofibrate. Cell Mol. Biol. 1988, 34:191-205.
9. Cimini A.M., Sulli A., Stefanini S., Serafini B., Moreno S., Rossi L., Giorgi M., Ceru M.P. Effects of di-(2-ethylhexyl)phthalate on peroxisomes of liver, kidney and brain of lactating rats and their pups. Cell Mol. Biol. (Noisy-le-grand) 1994, 40:1063-1076.
10. Das K.P., Grey B.E., Zehr R.D., Wood C.R., Butenhoff J.L., Chang S.C., Ehresman D.J., Tan Y.M., Lau C. Effects of perfluorobutyrate exposure during pregnancy in the mouse. Toxicol. Sci. 2008, 105:173-181.
11. Dostal L.A., Jenkins W.L., Schwetz B.A. Hepatic peroxisome proliferation and hypolipidemic effects of di(2-ethylhexyl)phthalate in neonatal and adult rats. Toxicol. Appl. Pharmacol. 1987, 87:81-90.
12. Fahl W.E., Lalwani N.D., Reddy M.K., Reddy J.K. Induction of peroxisomal enzymes in livers of neonatal rats exposed to lactating mothers treated with hypolipidaemic drugs. Role of drug metabolite transfer in milk. Biochem. J. 1983, 210:875-883.
13. Foreman J.E., Chang S.C., Ehresman D.J., Butenhoff J.L., Anderson C.R., Palkar P.S., Kang B.H., Gonzalez F.J., Peters J.M. Differential hepatic effects of perfluorobutyrate mediated by mouse and human PPAR-alpha. Toxicol. Sci. 2009, 110:204-211.
14. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:4312-4317.
15. Gonzalez F.J., Shah Y.M. PPARα: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008, 246:2-8.
16. Hays T., Rusyn I., Burns A.M., Kennett M.J., Ward J.M., Gonzalez F.J., Peters J.M. Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 2005, 26:219-227.
17. Klaunig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., Fenner-Crisp P.A. PPARα agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 2003, 33:655-780.
18. Lau C., Thibodeaux J.R., Hanson R.G., Narotsky M.G., Rogers J.M., Lindstrom A.B., Strynar M.J. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol. Sci. 2006, 90:510-518.
19. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., Gonzalez F.J. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell Biol. 1995, 15:3012-3022.
20. Liou J.S., Szostek B., Derito C.M., Madsen E.L. Investigating the biodegradability of perfluorooctanoic acid. Chemosphere 2010, 80:176-183.
21. Lou I., Wambaugh J.F., Lau C., Hanson R.G., Lindstrom A.B., Strynar M.J., Zehr R.D., Setzer R.W., Barton H.A. Modeling single and repeated dose pharmacokinetics of PFOA in mice. Toxicol. Sci. 2009, 107:331-341.
22. Maloney E.K., Waxman D.J. trans-Activation of PPARα and PPARγ by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 1999, 161:209-218.
23. Marsman D.S., Goldsworthy T.L., Popp J.A. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid. Carcinogenesis 1992, 13:1011-1017.
24. Miller D.B., Spence J.D. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 1998, 34:155-162.
25. Peters J.M. Mechanistic evaluation of PPAR-mediated hepatocarcinogenesis: are we there yet?. Toxicol. Sci. 2008, 101:1-3.
26. Peters J.M., Aoyama T., Cattley R.C., Nobumitsu U., Hashimoto T., Gonzalez F.J. Role of peroxisome proliferator-activated receptor α in altered cell cycle regulation in mouse liver. Carcinogenesis 1998, 19:1989-1994.
27. Peters J.M., Cattley R.C., Gonzalez F.J. Role of PPAR α in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997, 18:2029-2033.
28. Peters J.M., Cheung C., Gonzalez F.J. Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand?. J. Mol. Med. 2005, 83:774-785.
29. Reddy J.K., Azarnoff D.L., Hignite C.E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980, 283:397-398.
30. Shearer B.G., Hoekstra W.J. Recent advances in peroxisome proliferator-activated receptor science. Curr. Med. Chem. 2003, 10:267-280.
31. Singh I., Lazo O. Peroxisomal enzyme activities in brain and liver of pups of lactating mothers treated with ciprofibrate. Neurosci. Lett. 1992, 138:283-286.
32. Stefanini S., Mauriello A., Farrace M.G., Cibelli A., Ceru M.P. Proliferative response of foetal liver peroxisomes to clofibrate treatment of pregnant rats. A quantitative evaluation. Biol. Cell 1989, 67:299-305.
33. Stefanini S., Nardacci R., Farioli-Vecchioli S., Pajalunga D., Sartori C. Liver and kidney peroxisomes in lactating rats and their pups after treatment with ciprofibrate. Biochemical and morphometric analysis. Cell Mol. Biol. (Noisy-le-grand) 1999, 45:815-829.
34. Stefanini S., Serafini B., Nardacci R., Vecchioli S.F., Moreno S., Sartori C. Morphometric analysis of liver and kidney peroxisomes in lactating rats and their pups after treatment with the peroxisomal proliferator di-(2-ethylhexyl)phthalate. Biol. Cell 1995, 85:167-176.
35. Ullrich V., Diehl H. Uncoupling of monooxygenation and electron transport by fluorocarbons in liver microsomes. Eur. J. Biochem. 1971, 20:509-512.
36. White S.S., Calafat A.M., Kuklenyik Z., Villanueva L., Zehr R.D., Helfant L., Strynar M.J., Lindstrom A.B., Thibodeaux J.R., Wood C., Fenton S.E. Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring. Toxicol. Sci. 2007, 96:133-144.
37. Wilson G.N., King T., Argyle J.C., Garcia R.F. Maternal clofibrate administration amplifies fetal peroxisomes. Pediatr. Res. 1991, 29:256-262.
38. Wolf C.J., Fenton S.E., Schmid J.E., Calafat A.M., Kuklenyik Z., Bryant X.A., Thibodeaux J., Das K.P., White S.S., Lau C.S., Abbott B.D. Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicol. Sci. 2007, 95:462-473.
39. Wolf C.J., Takacs M.L., Schmid J.E., Lau C., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptor α by perfluoroalkyl acids of different functional groups and chain lengths. Toxicol. Sci. 2008, 106:162-171.
40. Wolf D.C., Moore T., Abbott B.D., Rosen M.B., Das K.P., Zehr R.D., Lindstrom A.B., Strynar M.J., Lau C. Comparative hepatic effects of perfluorooctanoic acid and WY 14,643 in PPAR-alpha knockout and wild-type mice. Toxicol. Pathol. 2008, 36:632-639.